These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26310827)

  • 1. Tumor Growth Inhibition via Occlusion of Tumor Vasculature Induced by N-Terminally PEGylated Retargeted Tissue Factor tTF-NGR.
    Brand C; Fröhlich M; Ring J; Schliemann C; Kessler T; Mantke V; König S; Lücke M; Mesters RM; Berdel WE; Schwöppe C
    Mol Pharm; 2015 Oct; 12(10):3749-58. PubMed ID: 26310827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factor.
    Schwöppe C; Zerbst C; Fröhlich M; Schliemann C; Kessler T; Liersch R; Overkamp L; Holtmeier R; Stypmann J; Dreiling A; König S; Höltke C; Lücke M; Müller-Tidow C; Mesters RM; Berdel WE
    J Med Chem; 2013 Mar; 56(6):2337-47. PubMed ID: 23496322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.
    Dreischalück J; Schwöppe C; Spieker T; Kessler T; Tiemann K; Liersch R; Schliemann C; Kreuter M; Kolkmeyer A; Hintelmann H; Mesters RM; Berdel WE
    Int J Oncol; 2010 Dec; 37(6):1389-97. PubMed ID: 21042706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.
    Bieker R; Kessler T; Schwöppe C; Padró T; Persigehl T; Bremer C; Dreischalück J; Kolkmeyer A; Heindel W; Mesters RM; Berdel WE
    Blood; 2009 May; 113(20):5019-27. PubMed ID: 19179306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
    Stucke-Ring J; Ronnacker J; Brand C; Höltke C; Schliemann C; Kessler T; Schmidt LH; Harrach S; Mantke V; Hintelmann H; Hartmann W; Wardelmann E; Lenz G; Wünsch B; Müller-Tidow C; Mesters RM; Schwöppe C; Berdel WE
    Oncotarget; 2016 Dec; 7(50):82458-82472. PubMed ID: 27738341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor.
    Brand C; Schliemann C; Ring J; Kessler T; Bäumer S; Angenendt L; Mantke V; Ross R; Hintelmann H; Spieker T; Wardelmann E; Mesters RM; Berdel WE; Schwöppe C
    Oncotarget; 2016 Feb; 7(6):6774-89. PubMed ID: 26735180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging.
    Persigehl T; Ring J; Bremer C; Heindel W; Holtmeier R; Stypmann J; Claesener M; Hermann S; Schäfers M; Zerbst C; Schliemann C; Mesters RM; Berdel WE; Schwöppe C
    Angiogenesis; 2014 Jan; 17(1):235-46. PubMed ID: 24136410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue-factor fusion proteins induce occlusion of tumor vessels.
    Schwöppe C; Kessler T; Persigehl T; Liersch R; Hintelmann H; Dreischalück J; Ring J; Bremer C; Heindel W; Mesters RM; Berdel WE
    Thromb Res; 2010 Apr; 125 Suppl 2():S143-50. PubMed ID: 20433995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-Energy Ultrasound Treatment Improves Regional Tumor Vessel Infarction by Retargeted Tissue Factor.
    Brand C; Dencks S; Schmitz G; Mühlmeister M; Stypmann J; Ross R; Hintelmann H; Schliemann C; Müller-Tidow C; Mesters RM; Berdel WE; Schwöppe C
    J Ultrasound Med; 2015 Jul; 34(7):1227-36. PubMed ID: 26112625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature.
    Kessler T; Bieker R; Padró T; Schwöppe C; Persigehl T; Bremer C; Kreuter M; Berdel WE; Mesters RM
    Clin Cancer Res; 2005 Sep; 11(17):6317-24. PubMed ID: 16144936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcoma.
    Brand C; Greve B; Bölling T; Eich HT; Willich N; Harrach S; Hintelmann H; Lenz G; Mesters RM; Kessler T; Schliemann C; Berdel WE; Schwöppe C
    PLoS One; 2020; 15(2):e0229271. PubMed ID: 32084238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.
    Schmidt LH; Stucke-Ring J; Brand C; Schliemann C; Harrach S; Muley T; Herpel E; Kessler T; Mohr M; Görlich D; Kreuter M; Lenz G; Wardelmann E; Thomas M; Berdel WE; Schwöppe C; Hartmann W
    Lung Cancer; 2017 Nov; 113():121-127. PubMed ID: 29110838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of fusion proteins for selective occlusion of tumor vessels.
    Kessler T; Schwöppe C; Liersch R; Schliemann C; Hintelmann H; Bieker R; Berdel WE; Mesters RM
    Curr Drug Discov Technol; 2008 Mar; 5(1):1-8. PubMed ID: 18537561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth.
    Seidi K; Jahanban-Esfahlan R; Monhemi H; Zare P; Minofar B; Daei Farshchi Adli A; Farajzadeh D; Behzadi R; Mesgari Abbasi M; Neubauer HA; Moriggl R; Zarghami N; Javaheri T
    Oncogene; 2018 Jul; 37(29):3967-3980. PubMed ID: 29662195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific tissue factor delivery using a tumor-homing peptide for inducing tumor infarction.
    Shi Q; Zhang Y; Liu S; Liu G; Xu J; Zhao X; Anderson GJ; Nie G; Li S
    Biochem Pharmacol; 2018 Oct; 156():501-510. PubMed ID: 30222966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
    Curnis F; Arrigoni G; Sacchi A; Fischetti L; Arap W; Pasqualini R; Corti A
    Cancer Res; 2002 Feb; 62(3):867-74. PubMed ID: 11830545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth.
    Yokoyama Y; Ramakrishnan S
    Cancer; 2005 Jul; 104(2):321-31. PubMed ID: 15952188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo NIRF imaging-guided delivery of a novel NGR-VEGI fusion protein for targeting tumor vasculature.
    Ma W; Li G; Wang J; Yang W; Zhang Y; Conti PS; Chen K
    Amino Acids; 2014 Dec; 46(12):2721-32. PubMed ID: 25182731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Arginine-glycine-aspartic polypeptide mediated truncated tissue factor therapy for colorectal carcinoma].
    Huang ZJ; Luo Q; Yan JH; Wang SY
    Zhonghua Wai Ke Za Zhi; 2010 Apr; 48(8):619-24. PubMed ID: 20646482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Humanized monoclonal antibody TNT-3-mediated truncated tissue factor for the treatment of H22 hepatoma-bearing mice].
    Huang ZJ; Wang R; Liu ZZ; Wang SY; Yan JH; Luo Q
    Zhonghua Zhong Liu Za Zhi; 2012 Apr; 34(4):249-53. PubMed ID: 22781034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.